All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my great pleasure to have a fireside chat with Disc Medicine. We have our CEO, John Quisel.
Yeah, great to be here.
Great to see you. All right. John, why don't you give yourself a minute or so overview Disc Medicine, without too much specificity, and we're going to dive into the conversation.
Sure. Great. Yeah. Disc Medicine, we've been public now for coming up on four years, and happy to say our whole pipeline appears to be advancing very successfully. We just had, I'll say the pipeline all focuses on controlling metabolism in red blood cells designed to address a variety of different red blood cell disorders. At this point, we just had a big phase III readout that was successful with our lead program, so that should be advancing towards commercialization. Our two phase II programs in myeloproliferative diseases appear to be progressing towards phase III. All in all, everything is moving very well right now.
Excellent. I totally agree. Okay, you have a couple pipeline, and then probably we'll focus first on the bitopertin in the EPP. After your very impressive phase III data, we talked with quite a few physician and even the patient group, through the public interview. They are very positive, first of all. And then one thing caught my attention is that they think bitopertin seems to be more tolerated, which is great, but on the efficacy side, maybe they're just not that into the data, they say it's pretty comparable, which I think you're pretty differentiated, although the study design is different. So how you would say, react to those, kind of a, how to say which endpoint on the efficacy side you think are very meaningful and then differentiated, and then what's the feedback you're getting from the broader physician and patient community?
Because we talked with a few, but you probably get to talk with a lot of more people.
Yeah, I think it's hard for me to make comparative statements, but I think the enthusiasm for bitopertin is very, very strong.
That's true.
As many people know, I think we were pursuing approval on an accelerated path. That ultimately didn't succeed. We got a CRL. That CRL, which happened in February, triggered a tremendous outpouring from the patient groups who were frustrated about not getting access to the drug on that kind of earlier basis.
As a result, those patients started to really come out to the public and tell their stories. If you read those stories, they're publicly available, they are reporting what I would say, really remarkable life-changing experiences with the product. At the KOL level, the mechanism addressing the reduction of protoporphyrin IX is viewed as a very powerful and important feature of the drug, right? It's the only product in development right now that really gets to the root cause of the disease.
That's right.
I think I was very happy to see in the phase III readout that both the patient experience as well as the fundamental mechanistic nature of the drug, both were captured in the data. The endpoints actually seemed to report that kind of fundamental effect. I think most remarkable was the reduction in phototoxic pain events. That was one of our secondaries, I think our first secondary endpoint.
We showed a little bit more than 70% reduction in pain attacks, which was almost identical to what we saw in phase II, by the way. We saw 75%. That was nominally stat sig. Now it was truly stat sig with a very good p-value.
Yep.
I think that profile of here's a drug that reduces the toxic metabolite that causes your disease, it will allow people to spend more time in light, and while spending more time in light, cause a greater than 70% reduction in the likelihood that you have a phototoxic pain attack, which is really the signature effect of the disease on a day-to-day basis in these patients. That's a fantastic profile.
Mm-hmm. Okay. I totally agree. Just a final point. You enroll the patient with prior SCENESSE, which is currently approved for EPP patient, and then with a washout period. Do you see the difference between those two groups, naive to SCENESSE versus experienced?
Yeah. So at this point in the phase III trial, we only have top line, so we don't have some of these kinds of secondary analyses. In the phase II trial, though, we had similar patients, and there was no difference.
Okay. How about U.S. versus Europe?
Yes. Well,
All right, that'sâ
We don't have that information yet.
âYeah.
Soon we'll have, I think, a scientific presentation, and when we do that, we'll start to be able to break out some of the subgroup analyses.
Yep. That's what people are interested to know.
Yeah.
But I believe it's going to be consistent, but just that's a oneâ
Yeah. I mean, the p-values are so robust
âThat's right.
it almost implies that every subgroup has to be favorable.
Got it. Okay. Good. You guided that you are going to resubmit the NDA by the end of the year, aiming for approval mid-next year. That's implying, again, six months, kind of the standard review period. Any gating factors before you can resubmit, and then how likely you can get earlier approval? Because
We all know the main need here.
Right. There are no gating factors, so we're just taking the data and plowing away to create all the documents. It really is only a submission around this clinical data, the phase III trial, as well as some pooled analyses of efficacy and safety across multiple trials. But there's CMC, we believe to be completely resolved. There will be no submission materials around that. Same is true for the non-clinical package.
We believe that review was completed as part of the last cycle of review earlier this year.
Okay.
So really just a review of the clinical data, and I think that is why people are asking us, "Can this go faster?
Yeah, that is right.
Obviouslyâ
Not much to review.
âRight. There is not objectively that much to review, so technically, when we resubmit, it is less of a six-month review period.
Yeah.
We are going to be eagerly asking the FDA whether they can move faster. The truth is, they are busy. They got other things going on, so they may well take their six months, but we will see.
Yeah. Okay. Good. I think just last week, we heard about the CNPV, that is a whole history. We do not need to open that topic.
Right.
But just because you were part of the CNPV program, then now they potentially will shelve. Any impact at all whatsoever? Then also with this resubmission, are you still considered as under the CNPV, or you have become like a standard?
No, we are not considered part of the CNPV anymore.
Oh.
I think that is actually beneficial.
That is right.
Better to just have a straightforward review.
Right.
But I will say, one of the benefits of the CNPV is we did get a lot of resources deployed from the FDA, and they were able to get very rapidly through the review of all the modules of the NDA. So I think when you see in the CRL that what they are really asking for is phase III data.
Yeah
I think that is literally all that is the only element that we are submitting with.
You addressed.
Yeah, exactly. That's been, appears to be addressed robustly.
That's right. Okay. I believe you have adolescent population in this phase III. How likely are you going to qualify for the pediatric voucher?
Right. We have a rare pediatric disease designation. We were able to enroll about 34 adolescent patients into the phase III trial. We haven't looked at the subgroup analyses yet, but we have general alignment that the disease is the same in adults and adolescents, so you can extrapolate the data from the adult population down into the adolescent population. Our assumption is we just need to see numerical benefit in the adolescent subgroup.
Yeah.
Just generally indicating that they are behaving about the same as the adults. That should allow us to progress towards a label that includes the age 12 and up.
Yeah.
The unmet need in that population is very high because there is actually no approved drug right now for those adolescents.
Sure.
If we get that, then I guess it does set up an opportunity for a PRV, which would be fantastic.
Yeah. We know the monetary value of the PRV. How about the ex-U.S. MAA filing, do you have any timeline guidance, and what is the overall ex-U.S., even U.S. commercial strategy? I know youâ
Right.
âYeah.
Yeah. I think we are all well aware of many of the challenges in ex-U.S. strategy nowadays, some of the MFN pressure on that. Our assessment is there are a lot of patients in Europe. The medical need is very, very high. We saw, for example, extremely rapid enrollment into our trials. We opened the trial in November. We enrolled about 100 patients in Europe and shut the trial down for enrollment points of view in March.
Cool.
Right? So it tells you that the demand in Europe, and there is concentration, right? The European healthcare system tends to be quite organized, so patients are concentrated at centers. So we think there is a good business to be had there.
For that reason, we are planning to move ahead with an MAA submission sometime next year. We will guide in a more granular way as we come into the end of the year.
But yeah, we look forward to providing access to drug in many of those countries there.
Mm. Okay. And then strategy-wise, you were thinking about, you're thinking about the partnership, or you want to go alone as well. Maybe talk about your EU versus the ex-U.S., U.S. and EU.
Yeah. I think you can do it. There's many precedents now for companies doing it on their own with a very lean infrastructure. Again, rare disease, relatively few sites. It does not take a giant infrastructure. If we felt like it did, then that would be the motivation to partner.
Mm-hmm. Got it. Okay. In terms of the market size, that's probably another debate among investors. Also, honestly, the current drug is not giving you too much good kind of reference. So you think 600 people, patients among the top centers, and then 1,000 among center of excellence. So how many of those patient have identified by you and your team, and then how accessible they will be available to you when the BITO is approved?
Sure. So we have 150 people in our long-term extension in the U.S. only. We have an expanded access program that we haven't provided the exact numbers yet, but it's ongoing, enrolling. It kind of resembles a clinical trial in terms of the number of patients that are accumulating there. That already is probably close to or exceeding even the number of patients who are on the one approved product, SCENESSE. So those are two efforts ongoing to provide access to patients to this therapy now. To your point, when you look at the top 100 centers or so in the claims data, we see about 1,600 patients there. We've had about 10 reps out in the field doing disease education, physician engagement, having conversations about what patients do they have.
Broadly speaking, there's a pretty good correlation between what the claims data has predicted about that group of patients and what we're finding. We can account now for the majority of those 1,600 patients, then we've started to find patients actually from the larger pool of 6,000 engaged patients that we see in the claims data. We've even identified some patients that are in the set of 8,000 patients that you see in the claims data who really only had one claim that could be from many years ago. We've been now able to find some of those patients as well. We're feeling very good about our trajectory of engagement with physicians, identification of where patients are, and the meter just is going up.
Yeah. Got it. I have to say, the patient enthusiasm about the drug is off the roof.
It's extraordinary.
Yeah.
I mean, we're so grateful and just so pleased to be able to do something that seems to be meaningful.
That's right.
Yeah.
Okay. How about the pricing? Because right now, the drug is about $300,000, if you're the full course, and this is a rare disease, we know you can price much higher. So with this profile and addressing the root cause, do you think, what's the range of the pricing you're considering?
Yeah. I mean, of course, we'll need to get our label and many more facts in place before we can really opine on a likely price for our product. If you look in porphyrias generally, there's one approved drug in erythropoietic protoporphyria. As we talked about, SCENESSE is priced at about $300,000 per year, requires surgical implantation, et cetera. If you look over in hepatic porphyria, Alnylam has a drug called GIVLAARI. It's priced now, I think, over $600,000 per year. Mechanistically, it's very similar to bitopertin. It works by affecting the heme biosynthetic pathway to reduce the accumulation of toxic metabolites. But so those are the two precedents in the porphyria space. I think if you look in rare disease generally, if you look at HAE, PNH, diseases of similar size to EPP, the price range is sitting around $400,000-$600,000 per year.
These are the rare disease price precedents that we see out there. We'll be taking all those into account as we get our final label and pieces of our puzzle come together.
Got it. Okay. Fantastic. I think that's a pretty good update on the BITO, and then maybe move on to your other pipeline, particularly for the heme, and then for the MF and the PV. You will have some updates at ASH, so maybe just give us some preview, what we're going to show, and then what should be the focus for those two datasets, or multiple datasets?
Yeah. ASH is always an exciting moment for us every year, probably the most significant for our company. So we'll have data from both of our pipeline assets, the phase II programs in myelofibrosis anemia. We'll have an additional cut of the open-label data. That will actually, we'll be presenting the data package that we bring to the FDA for our end of phase II meeting. That's an oral presentation, so a nice event, a lot of exposure there. Then we'll have a corporate call after the ASH conference, and on that call, we'll be able to summarize the output from our end of phase II meeting with the FDA, the attributes, where we've aligned on a phase III trial design, and how that's going to unfold next year.
Wow.
Yeah. This is exciting around myelofibrosis anemia. I think we'll get real closure and clarity about what the phase III program looks like. Then we'll also have data for the third program, the polycythemia vera.
That's right.
Fully enrolled in July, so I think that entire trial enrolled in about nine months as a phase II program. We showed already the initial data from cohort A, which was a Q2 weeks dosing. Now we will be able to show the Q4 weeks dosing. Our intention in the end is to have that be an in-home administration, auto-injector type presentation. Obviously, in the clinical trial, it is just a subQ approach. I think if we can show that that one-month dosing is working well, with similar efficacy to the other products in our space, then I think it shows that we are kind of on level footing with our competitors.
We will look at the safety tolerability profile and see whether we think there is an advantage to be going with, we are the only antibody that is approaching this field, and we are hopeful that that will provide some advantages to us.
Excellent. Okay, so for the MF, since you already had an end of phase II meeting, what kind of things you can say right now? The topic is, what could be the patient population for the pivotal, and then what the size, and then what is the end point?
Right.
Any surprise? You have been, I think it is not secret, you have some thoughts around the design and the population.
Sure.
Any surprise you will say at this point?
I mean, I think our base plan and expectation is that we see in phase II, the drug has remarkably broad applicability.
Yeah.
Right? Essentially, if you are a myelofibrosis anemic patient, you seem to benefit, or you have a very high chance of benefiting from our drug, right? The minor response rate, which is really what clinicians care about, sits at around 70%, right, which is unprecedented. Because we see that broad benefit running from the non-transfused patients to the transfused patients, people who are not on a JAK inhibitor therapy, people who are on a JAK inhibitor therapy, people who are on any one of the three different approved JAK therapies, they all benefit from the drug. The key thing for us is being able to design a phase III program that can deliver that kind of broad label.
Right.
Right? That's the commercial intent. We think that's the unmet medical need. It's a broad space. People have been looking for a treatment for anemia of myelofibrosis for multiple decades now.
Yeah.
We are hopeful that the FDA will see it that way too, be highly engaged and motivated to deliver a good therapy for these patients. The key around the phase III design is showing that we have a path to approach that whole broad set of patients. That is what we will hope to be able to share coming out of that meeting.
Got it. Okay. In terms of the emerging competitive landscape, you have a mutCALR and then JAK2. They all partially address anemia, I would have to say, but when I talk with the physician, they all think anemia, still have a lot of patient have unaddressed anemia or maybe worsening anemia post some of the trial. What is your feedback you got, the anemia, it may need to get higher or lower after, if assuming those pipeline also get approval future in the market?
Yeah. When you look at JAK inhibitor therapy, which is about half of MF patients are on some kind of JAK inhibitor, we now have a spectrum of agents that go from relatively weak JAK2 inhibitors to very, very strong JAK2 inhibitors. No surprise, the stronger the inhibition, it appears the efficacy is better, but you also have a much more profound anemia side effect, right? The more the field wants to push towards a stronger and stronger JAK inhibition, the more and more managing anemia in those patients is going to be a critical way of allowing patients to tolerate and access therapy. I think that our product in that setting of enabling JAK inhibitor therapy, that is going to be one of the important use cases for the product, and that is only going to get better.
When you look at the mutCALR mutant field, it is 25%-30% of MF patients. The initial data, I think, shows that if patients are also on a JAK inhibitor, there is no real change in hemoglobin status. If the patient came into the study anemic, they are going to still need anemia therapy. Then I think in the patients, so the subset of patients who are receiving monotherapy, mutCALR inhibitor, some of that data showed an improvement in hemoglobin, but I do not think they are really seeing full resolution of anemia as a problem for those patients. I think the motivation to manage anemia there, setting aside, we still need to see more data on really what happens to anemia in those patients with an mutCALR inhibitor. If you assume there is some benefit, I think there is still going to be desire.
It's not like you want to take your patient whose hemoglobin is at 7 g/dL, see them get to 8 g/dL, and say, "Oh, that's managed," right? There's still going to be desire to get them up to 10 g/dL, 11 g/dL, 12 g/dL, because that's where you see really marked improvement in quality of life, right? And that's what we've seen in our phase II study, and I think people are going to have a strong motivation to manage anemia and improve patient experience.
Yeah. Got it. Yeah. By the way, your mechanism is also very different, right?
It's completely orthogonal to everything else.
Yeah.
And quite benign. We're just mobilizing iron.
That is right. Okay. All right. For PV, it is getting a little bit more activity with one of the newly approved drug and then one acquisition.
Right.
This market is definitely evolving. What is your position as a monoclonal antibody, potentially once a month dosing? What kind of level of the efficacy you want to show to be a viable and commercially attractive, just on the efficacy side? Maybe we can talk about the tolerability as well.
Yeah. I mean, I think this represents a real potential shift in the way these patients are managed. You have about, I think, estimated 50,000 patients- 100,000 patients in the U.S. who are receiving regular phlebotomy as a way of basically inducing iron deficiency in the patients to manage their hematocrit and avoid thromboembolic events. With the lead product that the team there in this space, the pioneering effort with rusfertide showed is that when you restrict iron with a drug, it actually helps patients feel much better because they are no longer iron deficient, but nonetheless, you are able to manage hematocrit in a way that is more straightforward, right, and probably better for avoiding thromboembolic events. That is great to see. We are part of kind of a second wave of products seeking TMPRSS6 to increase endogenous hepcidin and accomplish iron restriction.
I think this is going to be a really important market for therapy, 50,000- 100,000 target patients. The price point established around the rusfertide program is estimated around $250,000 per year. I think there is plenty of room for us and a few competitors to explore, what is the best possible therapy for these patients. Like I said before, we are the only ones approaching this with an antibody.
I think antibodies do have a very reliable PK/PD relationship. They have a recognizable tolerability profile, tend to not have a lot of injection site reactions with antibodies. There are none of the characteristic side effects that you can sometimes have with nucleic acids. We're optimistic that the profile we can prove out in the end will be one that patients find to be quite advantageous. We're going to, as I mentioned, we'll show you the cohort B data, the Q4 weeks. If that's successful, then I think a Q4 week in-home administration profile can really compete with any kind of nucleic acid profile, and then it'll just be a question of which approach provides the best efficacy and the best patient experience.
Got it. Then, would this cohort two data at ASH mature enough for you to make decision, and then when you're going to have end of phase II meeting to potentially
Yeah
design the phase III?
Yeah. I think the data will be adequate. Obviously, it won't be the complete data from everybody, but the last patient enrolled in July, so we'll have several months of experience in cohort B for everyone. That will be enough for us to be definitive about progressing towards phase III.
The timing will be next year, you are going to have a chat with the FDA.
Exactly.
Then do the phase II. Okay, got it.
Right.
Just last one, I think we saw some very early preliminary data from sickle cell data.
Yeah.
Then this, I believe this is going to be early data at ASH. You will give us some updates. Then how excited about you about this program, and then what kind of data we are going to see there?
Yeah, I am excited. Phlebotomy has actually now become part of guideline for managing sickle cell disease patients in Europe. It's particularly in the SC subpopulation, which represents about 20% of patients who have a particular genotype where they have a lot of thromboembolic events, but they have a relatively high hemoglobin. That's always been, I think, a really interesting population because there's extensive case history data showing that if you achieve iron restriction by phlebotomy in those patients, it provides a meaningful clinical benefit, and that's why it's gone on guideline now in Europe. So really what we're trying to do there is exactly what we're already doing in PV, which is to say, "Hey, phlebotomy is not a great or comfortable way to achieve iron restriction.
If you do it with a drug, it's more reliable." I think generally patients feel better because they're not nutritionally deprived of the iron. So if we can just bring that same kind of drug regimen that we're doing in PV into sickle cell disease, we have a high degree of optimism that it'll provide a safe and effective therapy. Now, all we're going to see at ASH is single-digit numbers of patients.
Yep.
We'll see that the drug is mechanistically engaging. We'll see whether it's as safe as we think it will be. The first sign of efficacy would be if there's any kind of improvement in hemolysis numbers. That would tell you that we are in fact improving red cell quality. If we are, then sets the stage for expanding that trial further, gathering additional evidence, and then eventually, if we have enough conviction in the data, moving to a larger trial, looking at true clinical thromboembolic event type of endpoints.
Got it. Next step will be the phase II, and then looking at the thromboembolic event. That's the potential next step.
Yeah. I think phase I, II, they can kind of blend together. I think an expanded kind of signal-seeking study and then build the conviction for a pivotal.
Got it. Fantastic. Thank you so much, John, for the informative discussion, and thank you everyone for listening and watching.
Thank you.